JP Morgan Chase
AAPG

JP Morgan Chase’s Ascentage Pharma AAPG Stock Holding History

JP Morgan Chase’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-211
Closed -$8.31K – 7811
2025
Q2 		$8.31K Buy
+211
New +$5.56K ﹤0.01% 6344

Other funds holding AAPG

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
NIM
NEOS Investment Management Westport, Connecticut $19.8B AUM 31.12% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase's AAPG Position: Q3 2025 in Review

JP Morgan Chase sold out of Ascentage Pharma (AAPG) in Q3 2025, closing a stake of 211 shares — an estimated $8.31K sold.

JP Morgan Chase first reported a position in AAPG in Q2 2025 and held it in 1 quarter. The position peaked at $8.31K in Q2 2025. 14 funds tracked by Wall St. Rank hold AAPG as of Q3 2025.

  • JP Morgan Chase reported no remaining Ascentage Pharma position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 211 Ascentage Pharma shares in Q3 2025, an estimated $8.31K.
  • JP Morgan Chase first reported a position in Ascentage Pharma in Q2 2025 and held it in 1 quarter.
  • JP Morgan Chase's Ascentage Pharma position peaked at $8.31K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Ascentage Pharma as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.